Your session is about to expire
← Back to Search
Virus Therapy
Treatment for Diffuse Intrinsic Pontine Glioma
N/A
Waitlist Available
Research Sponsored by Oblato, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be younger than 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
Summary
To provide OKN-007 for compassionate use in patients with diffuse midline glioma, H3 K27-altered (DMG), including diffuse intrinsic pontine glioma (DIPG), pediatric and young adult patients with high-grade diffuse midline glioma will be treated under this Intermediate-sized expanded access treatment protocol.
Eligible Conditions
- Diffuse Intrinsic Pontine Glioma
- Diffuse Midline Glioma
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 5 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
Treatment Details
Find a Location
Who is running the clinical trial?
Oblato, Inc.Lead Sponsor
4 Previous Clinical Trials
104 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger